- Continued
progress on CBD patent formulas
- Update
on the development of three CBD formulas already under the provisory
patent
- Additional
three products at various stages with Bionatus
Earth Science Tech, Inc. (OTC: ETST), a biotechnology
company focused on cannabidiol (CBD), nutraceuticals, pharmaceuticals and
medical devices, shared progress on its CBD patent formulas in a recent press
release (http://ibn.fm/JHwIe).
The company has three new CBD formulas under the provisory patent and three
Bionatus products in various stages of development.
ETST is developing three CBD formulas already under the provisory
patent whose function is to maintain quality of life and prevent inflammation,
cancer and degenerative diseases. The company announced in March (http://ibn.fm/fmIFs) that it had
received a grant from the Government of Quebec earmarked for the pre-launch
process of these three CBD-based nutraceutical provisional patent products.
Research and development has been very promising on the
first two unique CBD formula products, a neuron protector and a breast
protector. The final formulation is currently being developed to assure the
longest possible shelf life using a yet to be determined natural protective
agent. The third CBD formula is a unique superfood formulated from a mix of
hemp oil and other vegetal oil(s), enriched with potent antioxidants and
designed to improve antioxidant ingestion.
ETST has two products in development, Propovit and a
reformulation of Bionatus, through a joint venture with Bionatus Laboratrio
Botnico of Brazil and its Canadian division, Bionatus Botanical Laboratories,
Inc. Propovit is used to help alleviate throat irritation, colds and bad
breath. The new formulation will be enriched with ETST hemp oil. The main
natural ingredient in Bionatus is the Guaco extract. Traditional uses of this
extract suppose anti-inflammatory and bronchial-dilation properties, properties
that ETST and Bionatus believe will be enriched with the addition of CBD. A
third product is also being planned by ETST and Bionatus, with details to be
shared soon.
The company intends to share further updates on its CBD IP
patent formulas as they progress.
For more information, visit the company’s website at www.EarthScienceTech.com
About MissionIR
MissionIR is
primarily focused on strategic communications. We have executed countless
communications programs to address the needs of companies ranging from
start-ups to established industry leaders, gaining valuable experience and the
expertise necessary to determine the most effective strategy for any given
situation.
For more information, visit www.MissionIR.com
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
